Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
51.7M
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
1.92M
-
Shares change
-
-286K
-
Total reported value, excl. options
-
$3.37M
-
Value change
-
-$379K
-
Number of buys
-
9
-
Number of sells
-
-8
-
Price
-
$1.76
Significant Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) as of Q2 2025
29 filings reported holding SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2025.
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.92M shares
of 51.7M outstanding shares and own 3.72% of the company stock.
Largest 10 shareholders include BVF INC/IL (918K shares), Sessa Capital IM, L.P. (458K shares), VANGUARD GROUP INC (282K shares), GEODE CAPITAL MANAGEMENT, LLC (84.8K shares), Pathstone Holdings, LLC (50.7K shares), Kovitz Investment Group Partners, LLC (19.2K shares), First PREMIER Bank (19K shares), CITADEL ADVISORS LLC (17.1K shares), Kestra Advisory Services, LLC (11.9K shares), and Creative Planning (11.9K shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.